Medical Marijuana Giant Aurora Will Soon Report Earnings, Here's What Investors Need To Know
Medical Marijuana Giant Aurora Will Soon Report Earnings, Here's What Investors Need To Know
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) has scheduled a conference call to discuss the results for its first quarter 2025 on Wednesday, August 7, 2024 at 8:00 am ET.
Aurora Cannabis Inc.（納斯達克：ACB）（tsx：ACB）已安排一次電話會議，討論2025年第一季度的業績，將於2024年8月7日星期三上午8:00 ET。
The Canadian medical marijuana giant will report its financial results for the first quarter of 2025 before the opening of markets that same day. CEO Miguel Martin and CFO Simona King will host the conference call and question and answer period.
這家加拿大醫用大麻巨頭將在當天市場開盤之前公佈其2025年第一季度的財務業績。首席執行官Miguel Martin和首席財務官Simona King將主持電話會議和問答環節。
Aurora made headlines last week as it was granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). The permits granted the company continued domestic cultivation, which has been underway for two years.
上週，極光大麻因在德國新的醫療大麻法案（MedCanG）下獲得德國聯邦藥品和醫療器械研究所（BfArM）的兩個許可證而成爲新聞頭條。這些許可證授予公司繼續國內種植的權利，這項工作已進行了兩年。
Pablo Zuanic, a seasoned marijuana stock analyst from Zuanic & Associates, recently highlighted the company's need to prove its growth strategies amid an increasingly competitive and uncertain global landscape.
來自Zuanic & Associates的經驗豐富的大麻股票分析師Pablo Zuanic最近強調了該公司在日益競爭和不確定的全球環境中證明其增長策略的需求。
"ACB is among the two largest medical cannabis companies globally and stands to benefit significantly from nascent international markets, which we estimate could see a tenfold increase over the next decade," Zuanic wrote.
"ACB是全球兩大醫用大麻公司之一，將受益於新興國際市場，我們估計未來十年其中市場規模可能增長十倍，" Zuanic寫道。
Read Also: Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say 'There's No Stepping Back' From Legalization Wave
閱讀也可以看到：另一家大麻先驅公司通過收購在德國擴大，而專家表示‘無法從合法化潮流中後退'
Aurora targets a long-term market share of 10% in the international medical marijuana market, potentially increasing its international medical marijuana sales to roughly CA$700 million ($505.8 million). Current annualized international proforma revenues are CA$100 million.
極光大麻的目標是在國際醫用大麻市場上獲得10%的長期市場份額，可能將其國際醫用大麻銷售額提高到大約CA$70000萬（$50580萬）。當前國際預估收入的年化水平爲CA$10000萬。
In its latest earnings report, the company said its global medical cannabis net revenue grew by 20% year-over-year to CA$45.6 million in the fourth quarter of fiscal 2023. The increase in net revenue1 of $7.7 million was primarily due to higher sales to Australia and Europe in the current period following the success of newly launched innovative cultivars in these markets.
在其最新的業績中，該公司表示，其全球醫用大麻淨營業收入同比增長20％，到2023財年第四季度的CA$4560萬。$770萬淨營收增長主要是由於在這些市場新推出創新品種後，在當前期間向澳大利亞和歐洲的銷售增加。
- Aurora Cannabis Launches 1.2g Resin Cartridges In Australia, Now Available For Doctors To Prescribe
- 極光大麻推出1.2克樹脂筆芯在澳大利亞，現在可以爲醫生開處方。
To learn more about cannabis stocks and investing, come join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
未經公允價值調整的綜合調整毛利率爲49％，去年同期爲CA31.6百萬。